GoodRx Holdings, Inc. (NASDAQ:GDRX) shares are up on Wednesday as the company expands access to Novo Nordisk A/S’ (NYSE:NVO) Wegovy HD, a higher dose GLP-1 treatment available for self-pay patients at $399 per month.

• GoodRx Holdings shares are advancing steadily. What’s driving GDRX shares up?

This move comes amid a growing demand for GLP-1 treatments, which reflects GoodRx’s ongoing efforts to simplify access to medications.

GoodRx is a platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually.

In March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of  Wegovy, marking an expansion of its treatment portfolio for adults with obesity.

Tiered Pricing Structure Offers Flexibility

Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost.

For patients, Wegovy HD offers an additional FDA-approved step-up option within the Wegovy portfolio, potentially helping eligible patients achieve greater weight-loss benefit without requiring them to switch to a different brand or care pathway.

GoodRx announced that the new Wegovy HD injection is now available to eligible self-pay patients, with pricing options scaling for multiple-month supplies.

Last week, GoodRx revealed that it is expanding access to Eli Lilly and Company's (NYSE:LLY) new oral GLP-1 medication, Foundayo.

GoodRx announced that eligible self-pay consumers can access Foundayo starting at $149 per month.

The company is also expanding access to Zepbound, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide.

Technical Indicators Show Short-Term Strength

GoodRx’s relative strength index (RSI) is at 56.74, which indicates neutral momentum, suggesting the stock is not currently overbought or oversold.

Additionally, the moving average convergence divergence (MACD) is above its signal line, indicating bullish momentum, which may attract buyers looking for upward movement.

  • Key Resistance: $2.50 — A level where selling pressure may increase.
  • Key Support: $2 — A level where buying interest may emerge.

Analyst Consensus & Recent Actions: The stock carries a Hold rating with an average price target of $3.73. Recent analyst moves include:

  • Wells Fargo: Overweight (Lowers target to $3.50 on March 4)
  • Citigroup: Buy (Lowers target to $3.50 on March 3)
  • Goldman Sachs: Neutral (Lowers target to $2.50 on March 2)

GDRX Stock Price Activity: GoodRx Holdings shares were up 2.69% at $2.29 at the time of publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock